Aclaris Therapeutics (ACRS) – Company Press Releases
-
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
-
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
-
Aclaris Therapeutics Provides Corporate Update
-
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
-
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
-
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
-
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
-
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
-
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
-
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
-
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
-
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
-
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
-
Aclaris Therapeutics Provides 2023 Outlook
-
Eric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the Helm
-
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
-
Aclaris Therapeutics Announces Key Leadership Transitions
-
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
-
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
-
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
-
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Expands Leadership Team
-
Aclaris Therapeutics Expands Leadership Team
-
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
-
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
-
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
-
Aclaris Therapeutics Expands Leadership Team
-
Aclaris Therapeutics Provides R&D Update
-
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
-
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
-
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
-
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
-
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
-
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
-
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
-
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
-
Aclaris Announces Pricing of Public Offering of Common Stock
Back to ACRS Stock Lookup
